Market capitalization | $37.88m |
Enterprise Value | $34.67m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.18 |
P/S ratio (TTM) P/S ratio | 1.29 |
P/B ratio (TTM) P/B ratio | 7.41 |
Revenue growth (TTM) Revenue growth | 115.55% |
Revenue (TTM) Revenue | $29.44m |
As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.
Dec '24 |
+/-
%
|
||
Revenue | 29 29 |
116%
116%
|
|
Gross Profit | 26 26 |
119%
119%
|
|
EBITDA | -1.21 -1.21 |
68%
68%
|
EBIT (Operating Income) EBIT | -1.25 -1.25 |
67%
67%
|
Net Profit | -1.83 -1.83 |
61%
61%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
InnoCan Pharma Corp. operates as a pharmaceutical tech company. Its segments include: Pharmaceuticals and Consumer Wellness. The Pharmaceuticals segment focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science. It involves two drug delivery technologies: LPT CBD- loaded liposome platform and CLX CBD-loaded exosomes platform. The Consumer Wellness segment develops and markets a wide portfolio of innovative and self-care products to promote a healthier lifestyle. The company was founded in October 2017 and is headquartered in Alberta, Canada.
Head office | Canada |
CEO | Iris Bincovich |
Founded | 2018 |
Website | www.innocanpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.